You are about to leave
this Takeda website
Takeda has no control over the content or presentation of the third-party site you are about to view.
Patient portrayal
Talk to your child's doctor about Vyvanse and explore the clinical study results below.
129 kids aged 6 to 12 with ADHD.
For the first 4 weeks, everyone in the study took Vyvanse. Researchers adjusted the dose as needed to find the right dose for each person.
At the beginning of the fifth week, half of the group continued to take Vyvanse. The other half was switched to sugar pill. Researchers and patients didn't know who got Vyvanse and who got the sugar pill.
At the end of the fifth week, during a single day, both groups were placed in a classroom-like setting. At 7 AM, everyone took their assigned medication—either Vyvanse or the sugar pill. During the day, children were given individual and group activities just like a real classroom.
During the classroom day, researchers with special training evaluated the children for ADHD behaviors using a scientific method called the SKAMP scale. The goal of the study was to use the part called SKAMP-D to measure behavior.
At the beginning of the sixth week, the group that had taken Vyvanse was switched to sugar pill, and the group that had taken sugar pill was switched to Vyvanse. At the end of the sixth week, patients were again evaluated in the same classroom-like setting using the SKAMP-D scale.
On the SKAMP-D scale, lower scores indicate improved behavior.
In one study of kids (aged 6-12) with ADHD, Vyvanse (lisdexamfetamine dimesylate) demonstrated ADHD symptom control for up to 13 hours, starting at 1.5 hours after taking it.*
Individual results may vary.
*Results based on the Swanson, Kotkin, Agler, M-Flynn, and Pelham Deportment Scores (SKAMP-D) subscale, a validated classroom assessment tool that measures behavior problems leading to classroom disruptions. It is not a measure of academic performance.
Duration of ADHD symptom control has not been studied in teens (ages 13-17).
Your child should not take Vyvanse if he or she:
290 kids aged 6 to 12 with ADHD
Patients were divided into 4 groups, receiving Vyvanse 30 mg, 50 mg, or 70 mg, or sugar pill.
Patients assigned to the 30 mg Vyvanse treatment received this amount for 4 weeks. Patients assigned to 50 mg Vyvanse treatment received 30 mg in the first week and 50 mg for the next 3 weeks. Patients assigned to 70 mg Vyvanse treatment received 30 mg in the first week, 50 mg in the second week, and then 70 mg for the next 2 weeks.
Clinicians measured symptom control in patients at the start of the study and during every week using the ADHD Rating Scale-IV (ADHD-RS-IV) measurement. Lower scores on the ADHD-RS-IV indicate better symptom control. Parents assessed their children's ADHD symptoms using the Conners' Parent Rating Scale (CPRS) at about 10 AM, 2 PM, and 6 PM. Lower scores indicate fewer symptoms.
†Based on Conners’ Parent Rating Scale
314 teens aged 13 to 17 with ADHD.
Patients were divided into 4 groups, receiving Vyvanse 30 mg, 50 mg, or 70 mg, or sugar pill.
Patients assigned to the 30 mg Vyvanse treatment received this amount for 4 weeks. Patients assigned to 50 mg Vyvanse treatment received 30 mg in the first week and 50 mg for the next 3 weeks. Patients assigned to 70 mg Vyvanse treatment received 30 mg in the first week, 50 mg in the second week, and then 70 mg for the next 2 weeks.
Clinicians measured symptom control in patients at the start of the study and during every week using the ADHD Rating Scale-IV (ADHD-RS-IV) total score measurement. Lower scores on the ADHD-RS-IV indicate better symptom control.
In a 4-week clinical study of teens (aged 13-17) with ADHD, Vyvanse (lisdexamfetamine dimesylate) was shown to improve the symptoms of ADHD.
‡Based on the ADHD Rating Scale IV (ADHD-RS-IV) Total Score
Individual results may vary.
Your child should take Vyvanse exactly as the doctor tells him or her to take it.
Before getting started on Vyvanse, it's important to know the potential risks of treatments.
Tell the doctor if your child:
157 children aged 6 to 17 with ADHD.
The study had 4 parts. The first part of the study was 4 weeks, followed by a 20-week-long period, then 2 weeks, and then 6 weeks.
In the first part, for 4 weeks, all patients were treated with Vyvanse to find the best dose for them. They continued taking their Vyvanse at the best daily dose for 20 weeks, but doses could be changed if necessary. In the third part, researchers evaluated all patients and collected information on their dose; no changes were allowed during this time. Patients who showed a high level of ADHD symptoms during this period did not continue in the study. In the fourth part, half the patients were switched to sugar pill, while the other half continued on Vyvanse. This part was double-blinded, meaning neither the patients nor the clinicians knew which patients received Vyvanse and which received the sugar pill.
Clinicians measured symptom control in patients at the start of the study and every week using the ADHD Rating Scale-IV (ADHD-RS-IV) measurement. Lower scores on the ADHD-RS-IV indicate better symptom control. The Clinical Global Impression-Severity (CGI-S) score was also measured.
Vyvanse is approved for maintenance treatment of ADHD in children between the
ages of 6 and 17.
§"Treatment failure" (loss of symptom control) was defined as a 50% or greater increase (worsening) in the ADHD-RS-IV Total Score and a 2-point increase or greater (worsening) in the Clinical Global Impression-Severity score, compared to scores at entry into the double-blind phase.
Information to help prepare you for the conversation with your child's doctor.
Learn more about dosing and administration for Vyvanse.
